Antagonist treatments targeting these pathways were found to reduce MDSCs levels in intestinal tissues and mitigate fibrosis symptoms, suggesting that strategies aimed at inhibiting CXCR2‐ and CCR2‐mediated MDSCs recruitment could offer a promising therapeutic approach for the treatment of intestinal fibrosis. Here, CXCR2 is linked to fibrosis.